While the direct administration of bNAbs has limitations (e.g. viral diversity and resistance), their study has established a consensus that immunogens targeting these specific sites on HIV-1 Env can enhance the potential for developing broadly effective vaccines that can contribute to better control and global prevention of HIV-1 infection. Here, ERVW-1 is linked to HIV-1 infection.